AMVUTTRA® subcutaneous injections are an FDA-approved medication that suppresses transthyretin (TTR) gene, primarily at the liver, by working as a small interfering RNA (siRNA) prescribed for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Transthyretin is a serum protein that normally transports vitamin A and thyroxine, but in hATTR amyloidosis, mutations in the TTR gene cause misfolded TTR proteins to accumulate as amyloid deposits in tissues, particularly in peripheral nerves and the heart. By reducing TTR production, AMVUTTRA helps decrease the formation of these harmful deposits. It is also approved for ATTR-CM (cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis) in adults to reduce heart-related death, hospital stays and urgent visits.
AMVUTTRA® infusion therapy works as a small interfering RNA (siRNA) therapeutic that interferes with the expression of the transthyretin (TTR) gene.
The out-of-pocket AMVUTTRA® price will vary depending on your insurance coverage. If you have questions about your coverage, contact your insurance provider.
Many patients with commercial insurance qualify for the AMVUTTRA® Co-pay Program which can help cover the out-of-pocket AMVUTTRA® price. For those without insurance, they may be eligible for the Genentech Patient Foundation. For more information on AMVUTTRA® financial resources and drug assistance programs, you may visit: www.actemra.com/ra/financial-support/assistance-options.html
No patient should go without necessary treatment due to financial limitations. If you have questions about financial assistance opportunities, contact a member of our Violet Health team.
AMVUTTRA® is a subcutaneous injection once every 3 months (quarterly) administered by one of our highly trained healthcare professionals.
Each dose being 25mg delivered via prefilled syringe. Your doctor will recommend vitamin A supplements since AMVUTTRA® reduces vitamin A levels in your blood.
Many patients experience improvement or stabilization of their symptoms over time, with clinical trials showing potential benefits in nerve function, quality of life and mobility.
The most common side effects of AMVUTTRA® include:
AMVUTTRA® may lead to problems such as poor night vision and increased risk for infections due to decreases in vitamin A. Your doctor will likely recommend vitamin A supplementation.
Injection site reactions may also occur but are typically mild in severity, decreased over time, and were reported in only about 4% of patients in clinical studies.
Your comfort during AMVUTTRA® infusion therapy at Violet Health is our priority. Our AMVUTTRA® patients enjoy walk-up parking, complimentary entertainment and snacks, and a team of highly trained providers during each treatment. Plus, Violet Health’s evening and weekend hours and convenient city and rural locations make it easier to schedule your appointments.
Violet Health Infusion Centers provides infusion therapy for patients with rare, chronic, or complex conditions in a comfortable, patient-centered atmosphere.
Before you attend your first appointment at Violet Health, please make sure to review the documents below. Please contact us if you have any questions!
Medical Director
Director of Partnerships
Simplify patient referrals and offer advanced treatment options with our infusion partnership program.
There may be a better way to manage your condition – explore infusion therapy.